JP2018500546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500546A5 JP2018500546A5 JP2017525337A JP2017525337A JP2018500546A5 JP 2018500546 A5 JP2018500546 A5 JP 2018500546A5 JP 2017525337 A JP2017525337 A JP 2017525337A JP 2017525337 A JP2017525337 A JP 2017525337A JP 2018500546 A5 JP2018500546 A5 JP 2018500546A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- scopolamine
- benzalkonium chloride
- rodent
- candidate agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 45
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 25
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 25
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 25
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 25
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 25
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 25
- 229960002646 scopolamine Drugs 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 241000283984 Rodentia Species 0.000 claims description 23
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 10
- 206010013774 Dry eye Diseases 0.000 claims description 8
- 206010015946 Eye irritation Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 231100000013 eye irritation Toxicity 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 210000004969 inflammatory cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086263P | 2014-12-02 | 2014-12-02 | |
| US62/086,263 | 2014-12-02 | ||
| PCT/US2015/063084 WO2016089807A1 (en) | 2014-12-02 | 2015-12-01 | Animal model for dry eye and methods of use of such animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500546A JP2018500546A (ja) | 2018-01-11 |
| JP2018500546A5 true JP2018500546A5 (enExample) | 2018-12-27 |
| JP6692808B2 JP6692808B2 (ja) | 2020-05-13 |
Family
ID=55024246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525337A Expired - Fee Related JP6692808B2 (ja) | 2014-12-02 | 2015-12-01 | ドライアイ用動物モデルおよびこうした動物の使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170360013A1 (enExample) |
| EP (1) | EP3226853B1 (enExample) |
| JP (1) | JP6692808B2 (enExample) |
| KR (1) | KR20170100483A (enExample) |
| CN (1) | CN107106553A (enExample) |
| AU (1) | AU2015355169A1 (enExample) |
| CA (1) | CA2967432A1 (enExample) |
| ES (1) | ES2759729T3 (enExample) |
| IL (1) | IL252077A0 (enExample) |
| MX (1) | MX2017007295A (enExample) |
| RU (1) | RU2706787C2 (enExample) |
| SG (1) | SG11201703572SA (enExample) |
| WO (1) | WO2016089807A1 (enExample) |
| ZA (1) | ZA201703052B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190068575A (ko) * | 2016-10-14 | 2019-06-18 | 이콤 메디칼 게엠베하 | 안구 표면 항상성의 확립, 회복 및 보존 방법 |
| WO2019202017A1 (en) | 2018-04-18 | 2019-10-24 | i.com medical GmbH | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| CN113519461A (zh) * | 2021-07-06 | 2021-10-22 | 江西中洪博元生物技术有限公司 | 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用 |
| WO2023215261A1 (en) * | 2022-05-02 | 2023-11-09 | Ocular Services On Demand, Llc | Mammalian eye models |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003532629A (ja) * | 1999-09-08 | 2003-11-05 | ワトソン ファーマシューティカルズ， インコーポレイテッド | 第４アンモニウム塩の経皮薬剤放出への使用 |
| JP5878172B2 (ja) * | 2010-07-29 | 2016-03-08 | ラボラトワール フルニエ エスアーエス | 炎症性眼疾患の治療／予防用化合物 |
-
2015
- 2015-12-01 US US15/532,527 patent/US20170360013A1/en not_active Abandoned
- 2015-12-01 RU RU2017118978A patent/RU2706787C2/ru not_active IP Right Cessation
- 2015-12-01 CA CA2967432A patent/CA2967432A1/en not_active Abandoned
- 2015-12-01 KR KR1020177012469A patent/KR20170100483A/ko not_active Withdrawn
- 2015-12-01 EP EP15816590.2A patent/EP3226853B1/en active Active
- 2015-12-01 JP JP2017525337A patent/JP6692808B2/ja not_active Expired - Fee Related
- 2015-12-01 MX MX2017007295A patent/MX2017007295A/es unknown
- 2015-12-01 CN CN201580065760.3A patent/CN107106553A/zh active Pending
- 2015-12-01 ES ES15816590T patent/ES2759729T3/es active Active
- 2015-12-01 WO PCT/US2015/063084 patent/WO2016089807A1/en not_active Ceased
- 2015-12-01 AU AU2015355169A patent/AU2015355169A1/en not_active Abandoned
- 2015-12-01 SG SG11201703572SA patent/SG11201703572SA/en unknown
-
2017
- 2017-05-03 ZA ZA2017/03052A patent/ZA201703052B/en unknown
- 2017-05-03 IL IL252077A patent/IL252077A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500546A5 (enExample) | ||
| Song et al. | Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina | |
| JP7082115B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| JP2012046483A5 (enExample) | ||
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2016539921A5 (enExample) | ||
| JP2010536797A5 (enExample) | ||
| RU2017118978A (ru) | Модель сухого кератоконъюнктивита на животных и способы применения таких животных | |
| PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| JP2015007136A5 (enExample) | ||
| Liu et al. | Metal chelator combined with permeability enhancer ameliorates oxidative stress-associated neurodegeneration in rat eyes with elevated intraocular pressure | |
| IL277088B2 (en) | Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury | |
| JP2017519799A5 (enExample) | ||
| JP2020531511A5 (enExample) | ||
| JP2016515623A5 (enExample) | ||
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| WO2017139336A1 (en) | Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition | |
| HRP20240703T1 (hr) | Telmisartan za profilaksu ili liječenje hipertenzije kod mačaka | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| RU2014126070A (ru) | Способы лечения и предотвращения глазных заболеваний | |
| HRP20230634T1 (hr) | Pripravci za liječenje oftalmoloških stanja | |
| US9974768B2 (en) | Pharmaceutical for improving dysphagia | |
| JP6153838B2 (ja) | 血管透過性抑制剤 |